Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Shares Outstanding (2023 - 2025)

Compass Therapeutics' Shares Outstanding history spans 3 years, with the latest figure at $178.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 29.39% year-over-year to $178.3 million; the TTM value through Dec 2025 reached $178.3 million, up 29.39%, while the annual FY2025 figure was $178.3 million, 29.39% up from the prior year.
  • Shares Outstanding for Q4 2025 was $178.3 million at Compass Therapeutics, roughly flat from $177.6 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $178.3 million in Q4 2025 and bottomed at $126.4 million in Q1 2023.
  • The 3-year median for Shares Outstanding is $137.6 million (2024), against an average of $141.0 million.
  • The largest YoY upside for Shares Outstanding was 29.39% in 2025 against a maximum downside of 0.5% in 2025.
  • A 3-year view of Shares Outstanding shows it stood at $127.7 million in 2023, then rose by 7.95% to $137.8 million in 2024, then grew by 29.39% to $178.3 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Shares Outstanding are $178.3 million (Q4 2025), $177.6 million (Q3 2025), and $138.3 million (Q2 2025).